Flexion’s strategy is to build a robust pipeline of locally administered therapies to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA).
FX201 is a novel, intra-articular gene therapy product candidate which utilizes a helper-dependent adenovirus (HDAd) vector based on human serotype 5 (Ad5) that is designed to transfer a gene to cells in the joint to produce an anti-inflammatory protein, interleukin-1 receptor antagonist (IL-1Ra), under the control of an inflammation-sensitive promoter. Inflammation is a known cause of pain, and chronic inflammation is thought to play a major role in the progression of OA. By persistently suppressing inflammation, Flexion believes FX201 holds the potential to provide long-term pain relief and functional improvement, and to modify the disease.
FX301 is a locally administered NaV1.7 inhibitor product candidate, known as funapide, formulated for extended-release in a thermosensitive hydrogel. The initial development of FX301 is intended to support administration as a peripheral nerve block for control of post-operative pain. FX301 has the potential to provide effective pain relief while preserving motor function. The company anticipates initiating FX301 clinical trials in 2021.